Nvidia-backed AI firm Iambic unveils drug discovery ‘breakthrough’
Press
This is some text inside of a div block.
October 29, 2024
Related announcements
Iambic Shares Clinical Data from Ph1/1B Study of IAM1363, a Highly Selective Type-2 HER2 Inhibitor, Demonstrating Monotherapy Activity in Heavily Pretreated Patients with HER2 Alterations, at the 2025 ESMO Congress
Iambic Shares Clinical Data from Ph1/1B Study of IAM1363, a Highly Selective Type-2 HER2 Inhibitor, Demonstrating Monotherapy Activity in Heavily Pretreated Patients with HER2 Alterations, at the 2025 ESMO Congress
Iambic Therapeutics Announces the Addition of Shalini Sharp to its Board of Directors
Iambic Therapeutics Announces the Addition of Shalini Sharp to its Board of Directors
Iambic to Present New Pre-Clinical NSCLC Data for IAM1363, a Selective Type II Inhibitor for HER2 Cancers, at the 2025 World Conference on Lung Cancer